Phaseline

Targets › UGT1A1

UGT1A1 (UDP-glucuronosyltransferase 1A1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine; next expected readout Nov 2027.

[Isoform 1]: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds. (UniProt, P22309)

Open in Phaseline: the race on UGT1A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GenethonGNT0003
AAV8 vector carrying UGT1A1 transgene for gene therapy
UGT1A1Phase 2Crigler-Najjar SyndromeSep 2030
Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of HealthcareGT-UGT1A1-AAV8-02
AAV8-mediated gene therapy delivering UGT1A1 gene
UGT1A1Phase 1Crigler-Najjar Syndrome Type INov 2027

Conditions

Crigler-Najjar Syndrome Type I (1) Crigler-Najjar Syndrome (1)

Modalities

other (1), mixed (1)

Companies

Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare (1) Genethon (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.